Source comparison
MK-677 in Your 20s: Dosing Comparison
20–30 years 10–15mg daily High baseline GH pulse amplitude; lower dose prevents receptor saturation and premature desensitization 30–50 ng/mL above baseline 12–16 weeks on, 4–8 weeks off Optimal risk-to-benefit ratio; preserves long-term receptor sensitivity 3
This comparison does not assign a generated winner or score.
- 20–30 years
- 10–15mg daily
- High baseline GH pulse amplitude; lower dose prevents receptor saturation and premature desensitization
- 30–50 ng/mL above baseline
- 12–16 weeks on, 4–8 weeks off
- Optimal risk-to-benefit ratio; preserves long-term receptor sensitivity
- 30–40 years
- 15–20mg daily
- Moderate GH decline begins; slightly higher dose compensates without overshooting
- 40–60 ng/mL above baseline
- 16–20 weeks on, 6–8 weeks off
- Balanced approach as endogenous secretion wanes
- 40–50 years
- 20–25mg daily
- Significant age-related GH suppression; higher dose required to achieve therapeutic IGF-1 targets
- 50–70 ng/mL above baseline
- 20–24 weeks on, 8 weeks off
- Standard adult dosing reflects reduced receptor density
- 50+ years
- 25mg daily
- Maximal age-related decline; highest dose justified by diminished natural secretion
- 60–80 ng/mL above baseline
- Continuous or 24+ weeks on
- Receptor desensitization risk lower due to baseline suppression